NCT02390427View on ClinicalTrials.gov

Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

April 20, 2015

Primary Completion Date

December 31, 2022

Study Completion Date

July 31, 2024

Conditions
Metastatic Breast CancerRecurrent Breast Cancer
Interventions
DRUG

Taselisib

DRUG

Trastuzumab emtansine

DRUG

Pertuzumab

DRUG

Trastuzumab

DRUG

Paclitaxel

Trial Locations (3)

37203

Sarah Cannon Research Institute, Nashville

02114

Massachusetts General Hospital, Boston

02215

Dana Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Otto Metzger, MD

OTHER